Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
复制标题
DOI：
10.1183/09031936.00193908
复制
发表时间：
2009-09-01
影响因子：
24.3
通讯作者：
Vestbo, J.
中科院分区：
文献类型：
--
作者：
Crim, C.;Calverley, P. M. A.;Vestbo, J.
吸入性皮质类固醇（ICS）在降低慢性阻塞性肺疾病（COPD）相关加重频率方面非常重要。然而，对相关感染的风险知之甚少。在对COPD健康革命（TORCH）研究的事后分析中，我们分析并确定了在这项随机、双盲试验中肺炎不良事件报告的潜在风险因素，该试验比较了每日两次吸入沙美特罗（SAL）50 μ g，丙酸氟替卡松（FP）500 μ g，尽管安慰剂组的退出率较高，但在调整治疗时间后，FP和SFC治疗组报告的肺炎发生率较高（分别为84和88/1000治疗年）与SAL和安慰剂（分别为52和52/1000治疗年）相比。肺炎的危险因素为年龄≥ 55岁，1秒用力呼气量
Inhaled corticosteroids (ICS) are important in reducing exacerbation frequency associated with chronic obstructive pulmonary disease (COPD). However, little is known about the risk of associated infections.In a post hoc analysis of the TOwards a Revolution in COPD Health (TORCH) study, we analysed and identified potential risk factors for adverse event reports of pneumonia in this randomised, double-blind trial comparing twice-daily inhaled salmeterol (SAL) 50 mu g, fluticasone propionate (FP) 500 mu g, and the combination (SFC) with placebo in 6,184 patients with moderate-to-severe COPD over 3 yrs.Despite a higher withdrawal rate in the placebo arm, after adjusting for time on treatment, a greater rate of pneumonia was reported in the FP and SFC treatment arms (84 and 88 per 1,000 treatment-yrs, respectively) compared with SAL and placebo (52 and 52 per 1,000 treatment-yrs, respectively). Risk factors for pneumonia were age >= 55 yrs, forced expiratory volume in 1 s